Dyadic International Total Assets 2011-2026 | DYAI

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Dyadic International

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
9.95 M	9.93 M	8.22 M	13.7 M	21.3 M	30.1 M	37.5 M	43.3 M	50.7 M	58.7 M	76.7 M	8.54 M	14.9 M	12.9 M	10.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
76.7 M	8.22 M	27.1 M

Quarterly Total Assets Dyadic International

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
11.7 M	8.14 M	9.93 M	10.8 M	10.6 M	12.7 M	8.22 M	9.26 M	11.1 M	12.8 M	13.7 M	15.2 M	17.2 M	18.5 B	21.3 M	23.9 M	26.4 M	28.3 M	30.1 M	30.1 M	30.1 M	30.1 M	37.5 M	37.5 M	37.5 M	37.5 M	43.3 M	43.3 M	43.3 M	43.3 M	50.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
18.5 B	8.14 M	622 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.85	3.24 %	$ 9.26 B	Australia
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Alnylam Pharmaceuticals ALNY	4.97 B	$ 322.18	-3.36 %	$ 42.2 B	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
Burford Capital Limited BUR	3.11 B	$ 4.71	-0.53 %	$ 766 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Cabaletta Bio CABA	165 M	$ 3.51	3.09 %	$ 353 M	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Aligos Therapeutics ALGS	88.5 M	$ 7.72	4.04 %	$ 76.3 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	18.2 M	-	-18.52 %	$ 27.3 M	Britain
Applied Therapeutics APLT	54.8 M	-	-	$ 8.42 M	USA
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Brainstorm Cell Therapeutics BCLI	1.02 M	-	-2.5 %	$ 5.88 M	USA
Amphastar Pharmaceuticals AMPH	1.63 B	$ 22.0	1.48 %	$ 1.03 B	USA
CymaBay Therapeutics CBAY	435 M	-	-	$ 3.45 B	USA
BioNTech SE BNTX	22 B	$ 101.75	2.29 %	$ 27.2 B	Germany
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	21.4 M	-	5.93 %	$ 314 M	Canada
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 3.07	-3.15 %	$ 5.05 M	Israel
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Galectin Therapeutics GALT	19.5 M	$ 2.25	-12.11 %	$ 144 M	USA
ContraFect Corporation CFRX	20.7 M	-	-5.16 %	$ 5.39 M	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	377 M	$ 1.38	-10.97 %	$ 355 M	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Grifols, S.A. GRFS	21.4 B	$ 8.6	-1.04 %	$ 6.83 B	Spain
Aquestive Therapeutics AQST	160 M	$ 4.28	0.94 %	$ 458 M	USA
Arcutis Biotherapeutics ARQT	433 M	$ 23.69	-3.64 %	$ 3.01 B	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
Autolus Therapeutics plc AUTL	589 M	$ 1.59	6.71 %	$ 423 M	Britain
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
Checkpoint Therapeutics CKPT	7.47 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	35 M	-	-16.75 %	$ 25.8 M	USA
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
Clearside Biomedical CLSD	34 M	-	-	$ 25.3 M	USA
Celldex Therapeutics CLDX	583 M	$ 33.63	-0.72 %	$ 2.23 B	USA